Methods of predicting ancestral virus sequences and uses thereof

Patent metadata

Field	Value
Publication number	US-2023287359-A1
Application number	US-202318308590-A
Country	US
Kind code	A1
Filing date	Apr 27, 2023
Priority date	Oct 11, 2013
Publication date	Sep 14, 2023
Grant date	—

Abstract

Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.

First claim

1 . (canceled)

2 . A method comprising:
administering a plurality of recombinant adeno-associated virus (rAAV) particles to a subject in need thereof, wherein each rAAV particle comprises (i) a transgene and (ii) one or more AAV capsid polypeptides that comprise an amino acid sequence according to SEQ ID NOs: 19, 20, 21, 22, 23, 24, 25, or 26, and wherein the transgene is within the rAAV particle.

3 . The method of claim 2 , wherein the one or more AAV capsid polypeptides comprise the sequence of SEQ ID NO: 19.

4 . The method of claim 2 , wherein the one or more AAV capsid polypeptides comprise the sequence of SEQ ID NO: 20.

5 . The method of claim 2 , wherein the one or more AAV capsid polypeptides comprise the sequence of SEQ ID NO: 21.

6 . The method of claim 2 , wherein the one or more AAV capsid polypeptides comprise the sequence of SEQ ID NO: 22.

7 . The method of claim 2 , wherein the one or more AAV capsid polypeptides comprise the sequence of SEQ ID NO: 23.

8 . The method of claim 2 , wherein the one or more AAV capsid polypeptides comprise the sequence of SEQ ID NO: 24.

9 . The method of claim 2 , wherein the one or more AAV capsid polypeptides comprise the sequence of SEQ ID NO: 25.

10 . The method of claim 2 , wherein the one or more AAV capsid polypeptides comprise the sequence of SEQ ID NO: 26.

11 . The method of claim 2 , wherein the method is a method of vaccinating the subject.

12 . The method of claim 2 , wherein the method is a method of delivering gene therapy to the subject.

13 . The method of claim 2 , wherein the subject is a human.

14 . The method of claim 2 , wherein the plurality of rAAV particles are administered in a composition comprising a pharmaceutically acceptable carrier.

15 . The method of claim 2 , wherein the plurality of rAAV particles transduces or infects cells in the subject.

16 . The method of claim 15 , wherein the cells are ear cells.

17 . The method of claim 16 , wherein the ear cells are inner ear cells.

18 . The method of claim 2 , wherein a therapeutically effective dose of the rAAV particles is administered.

19 . A method of vaccinating or delivering gene therapy to a subject, the method comprising:
administering a therapeutically effective dose of recombinant adeno-associated virus (rAAV) particles to a subject, wherein each rAAV particle comprises (i) a transgene and (ii) one or more AAV capsid polypeptides that comprise an amino acid sequence according to SEQ ID NOs: 19, 20, 21, 22, 23, 24, 25, or 26, and wherein the transgene is within the rAAV particle.

20 . The method of claim 19 , wherein the rAAV particles transduce or infect cells in the subject.

21 . A method of delivering a transgene to a subject, the method comprising:
obtaining recombinant adeno-associated virus (rAAV) particles, wherein each rAAV particle comprises (i) one or more AAV capsid polypeptides and (ii) a transgene located within the rAAV particle, wherein the one or more AAV capsid polypeptides comprise an amino acid sequence according to SEQ ID NO: 19, 20, 21, 22, 23, 24, 25, or 26; and administering to the subject in need thereof a therapeutically effective amount of the rAAV particles.

22 . The method of claim 21 , wherein obtaining the one or more rAAV particles comprises purifying.

Assignees

• Massachusetts Eye & Ear Infirmary
• Schepens Eye Res Inst

Inventors

• Vandenberghe Luk H
• Zinn Eric

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C07K14/005 Primary

  from viruses · CPC title

• C07K14/075 Primary

  Adenoviridae · CPC title

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N15/86

  Viral vectors · CPC title